Wyeth Pharmaceuticals Introduces Innovative Hemophilia Program to Address Insurance Coverage Concerns

— New Program Provides Up to 1 Year of Free Factor During Lapse in Insurance Coverage —

Collegeville, Pa., (June 1,2005) — Continuing its support of the hemophilia community, Wyeth Pharmaceuticals, a division of Wyeth (NYSE:WYE), today unveiled the Wyeth Factor Resource Program^TM. The Wyeth Factor Resource Program consists of three individual programs, which are the Insurance-Coverage Program, Patient Assistance Program, and Reimbursement-Information Line. The Insurance-Coverage Program provides up to 1 year or 200,000 IU maximum of free hemophilia product to eligible participants experiencing a lapse in insurance coverage. In addition, Insurance-Coverage Program participants will receive assistance tracking their insurance cap usage and identifying alternate sources of insurance.

Unlike other programs, participants in the Insurance-Coverage Program are not required to earn certificates, coupons, or points to qualify for free product. To be eligible for program benefits, program participants must have used a Wyeth hemophilia product for the last 3 consecutive months at the time of application.

Insurance-Coverage Program participants will receive periodic, confidential updates on their insurance use. Individuals close to reaching their annual or lifetime insurance caps will be offered assistance from a program specialist to identify new options for health care insurance coverage. Program participants who are experiencing a lapse in coverage will receive free factor product for up to 1 year while program specialists work with them to secure new health care insurance.

"We recognize that medical insurance coverage is a concern for many people in the hemophilia community, so we created this program to provide a safety net and a measure of reassurance," said Robert J. Dufour, Assistant Vice President & Global Business Manager — Hemophilia at Wyeth. The amount of product available to participants in the Insurance-Coverage Program is based upon a percentage of their previous year's usage. Factor needed for surgery for participants who are receiving free product from the program is not deducted from the participant's yearly allowance, but is applied to the 200,000 IU maximum.

The Insurance-Coverage Program is available to individuals with either private or government health insurance who have been using a Wyeth hemophilia product — either ReFacto^® Antihemophilic Factor (Recombinant) or BeneFIX Coagulation Factor IX (Recombinant) — for 3 consecutive months at the time of application.

Program enrollment information is available from the Wyeth Web site, www.hemophiliavillage.com; the Wyeth Hemophilia Hotline (888-999-2349); or from a local Wyeth representative.

This document is in PDF (portable document format). PDF files require Adobe® Reader®; click here to download this free program.

Hemophilia is a rare, inherited blood clotting disorder for which there currently is no cure. People with hemophilia are deficient in one of the key proteins — either factor VIII (hemophilia A) or factor IX (hemophilia B) — that are vital in the clotting cascade to prevent bleeding. Both forms of hemophilia are characterized by spontaneous hemorrhages or prolonged bleeding, typically into joints and soft tissue. In the United States, nearly 4,000 people have hemophilia B and between 15,000 and 17,000 people have hemophilia A.

BeneFIX is indicated for the control and prevention of hemorrhagic episodes in patients with hemophilia B (congenital factor IX deficiency or Christmas disease), including control and prevention of bleeding in surgical settings.

BeneFIX is not indicated for the treatment of other factor deficiencies (eg, factors II, VII, VIII and X) nor the treatment of hemophilia A patients with inhibitors to factor VIII, nor the reversal of coumarin-induced anticoagulation, nor the treatment of bleeding due to low levels of liver-dependent coagulation factors.

As with the intravenous administration of any protein product, common adverse reactions may include headache, fever, chills, flushing, nausea, vomiting, or tiredness. Allergic-type hypersensitivity reactions, including anaphylaxis, have been reported for all factor IX products. Patients should be informed of the early symptoms and signs of hypersensitivity reactions. Patients should discontinue use of the product and contact their health care provider immediately and/or seek emergency care if any hypersensitivity reactions occur. BeneFIX may be contraindicated in patients with a known history of hypersensitivity to hamster protein. The accompanying diluent vial may contain dry natural rubber that may cause hypersensitivity reactions in persons with known or possible latex sensitivity.

About ReFacto
ReFacto is indicated for the control and prevention of hemorrhagic episodes and for surgical prophylaxis and for short-term routine prophylaxis to reduce the frequency of spontaneous bleeding episodes in patients with hemophilia A. The effect of regular routine prophylaxis on long-term morbidity and mortality is unknown.

As with the intravenous administration of any protein product, adverse reactions may include headache, fever, chills, flushing, nausea, vomiting, tiredness, or symptoms of allergic reactions. The remote possibility exists for hypersensitivity to non-human mammalian proteins. Known hypersensitivity to mouse or hamster proteins may be a contraindication to the use of ReFacto. Allergic reactions such as hives, itching, difficulty breathing, rapid heart rate, light-headedness and anaphylaxis have been reported for all factor VIII products. Patients should discontinue use of the product and contact their health care provider immediately and/or seek emergency care if any of these symptoms occur.

Please see the Prescribing Information for both products at www.hemophiliavillage.com.

About Wyeth
Wyeth Pharmaceuticals, a division of Wyeth (NYSE:WYE), has leading products in the areas of women's health care, cardiovascular disease, central nervous system, inflammation, transplantation, hemophilia, oncology, vaccines, and nutritional products. Wyeth is one of the world's largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing, and marketing of pharmaceuticals, vaccines, biotechnology products, and nonprescription medicines that improve the quality of life for people worldwide. The Company's major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare, and Fort Dodge Animal Health.

The statements in this press release that are not historical facts are forward-looking statements based on current expectations of future events that involve risks and uncertainties including, without limitation, risks associated with the inherent uncertainty of the timing and success of pharmaceutical research, product development, manufacturing, commercialization, economic conditions including interest and currency exchange rate fluctuations, changes in generally accepted accounting principles, the impact of competitive or generic products, trade buying patterns, wars or terrorist acts, product liability and other types of lawsuits, the impact of legislation and regulatory compliance and obtaining reimbursement, favorable drug pricing, access and other approvals, environmental liabilities, and patent, and other risks and uncertainties, including those detailed from time to time in the Company's periodic reports, including current reports on Form 8-K, quarterly reports on Form 10-Q and the annual report on Form 10-K, filed with the Securities and Exchange Commission. Actual results may vary materially from the forward-looking statements. The Company assumes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.

Back to News